NVIDIA and Partners Launch Agentic AI Blueprints to Automate Work for Every Enterprise
New NVIDIA AI Blueprints for building agentic AI applications are poised to help enterprises everywhere automate work. With the blueprints, developers can now
Nvidia
Nvidia
NVIDIA Enhances Three Computer Solution for Autonomous Mobility With Cosmos World Foundation Models
Autonomous vehicle (AV) development is made possible by three distinct computers: NVIDIA DGX systems for training the AI-based stack in the data center,
Nvidia
NVIDIA Announces Nemotron Model Families to Advance Agentic AI
Artificial intelligence is entering a new era — agentic AI — where teams of specialized agents can help people solve complex problems and
Nvidia
New GeForce RTX 50 Series GPUs Double Creative Performance in 3D, Video and Generative AI
GeForce RTX 50 Series Desktop and Laptop GPUs, unveiled today at the CES trade show, are poised to power the next era of
Nvidia
Now See This: NVIDIA Launches Blueprint for AI Agents That Can Analyze Video
The next big moment in AI is in sight — literally. Today, more than 1.5 billion enterprise level cameras deployed worldwide are generating
Media
Nvidia stock rebounds after optimistic forecast for ‘Age of AI’
Nvidia released its earnings report on Wednesday and projected that fourth-quarter sales were above Wall Street estimates, but investors balked as those figures
Media
NVIDIA Announces Financial Results for Third Quarter Fiscal 2025
SANTA CLARA, Calif., Nov. 20, 2024 (GLOBE NEWSWIRE) — NVIDIA (NASDAQ: NVDA) today reported revenue for the third quarter ended October 27, 2024,
Media
Nvidia to report third-quarter earnings after the bell – Key Points
In August, Nvidia said it expected about "several billion" in Blackwell sales during the January quarter. ​Read More
Media
5 Things to Know Before the Stock Market Opens
​Post Content  Read More U.S. stock futures are lower to close a losing week following the post-election rally; shares of Domino’s Pizza (DPZ) and
Media
AbbVie: EMPOWER-1 and EMPOWER-2 Phase 2 clinical trials did not meet their primary endpoint
AbbVie Provides Update on Phase 2 Results for Emraclidine in Schizophrenia *EMPOWER-1 and EMPOWER-2 Phase 2 clinical trials did not meet their primary